496 related articles for article (PubMed ID: 20206418)
21. Hsp90 inhibitors and drugs from fragment and virtual screening.
Roughley S; Wright L; Brough P; Massey A; Hubbard RE
Top Curr Chem; 2012; 317():61-82. PubMed ID: 21647838
[TBL] [Abstract][Full Text] [Related]
22. Pharmacophore modeling and in silico screening for new KDR kinase inhibitors.
Yu H; Wang Z; Zhang L; Zhang J; Huang Q
Bioorg Med Chem Lett; 2007 Apr; 17(8):2126-33. PubMed ID: 17306530
[TBL] [Abstract][Full Text] [Related]
23. Virtual screening of cathepsin k inhibitors using docking and pharmacophore models.
Ravikumar M; Pavan S; Bairy S; Pramod AB; Sumakanth M; Kishore M; Sumithra T
Chem Biol Drug Des; 2008 Jul; 72(1):79-90. PubMed ID: 18498326
[TBL] [Abstract][Full Text] [Related]
24. Structure-based approach to pharmacophore identification, in silico screening, and three-dimensional quantitative structure-activity relationship studies for inhibitors of Trypanosoma cruzi dihydrofolate reductase function.
Schormann N; Senkovich O; Walker K; Wright DL; Anderson AC; Rosowsky A; Ananthan S; Shinkre B; Velu S; Chattopadhyay D
Proteins; 2008 Dec; 73(4):889-901. PubMed ID: 18536013
[TBL] [Abstract][Full Text] [Related]
25. Hsp90 inhibitors, part 1: definition of 3-D QSAutogrid/R models as a tool for virtual screening.
Ballante F; Caroli A; Wickersham RB; Ragno R
J Chem Inf Model; 2014 Mar; 54(3):956-69. PubMed ID: 24564321
[TBL] [Abstract][Full Text] [Related]
26. Generation of predictive pharmacophore models for CCR5 antagonists: study with piperidine- and piperazine-based compounds as a new class of HIV-1 entry inhibitors.
Debnath AK
J Med Chem; 2003 Oct; 46(21):4501-15. PubMed ID: 14521412
[TBL] [Abstract][Full Text] [Related]
27. Pharmacophore modeling and virtual screening to identify potential RET kinase inhibitors.
Shih KC; Shiau CW; Chen TS; Ko CH; Lin CL; Lin CY; Hwang CS; Tang CY; Chen WR; Huang JW
Bioorg Med Chem Lett; 2011 Aug; 21(15):4490-7. PubMed ID: 21724393
[TBL] [Abstract][Full Text] [Related]
28. A novel class of Hsp90 inhibitors isolated by structure-based virtual screening.
Park H; Kim YJ; Hahn JS
Bioorg Med Chem Lett; 2007 Nov; 17(22):6345-9. PubMed ID: 17869098
[TBL] [Abstract][Full Text] [Related]
29. Discovery of novel HIV entry inhibitors for the CXCR4 receptor by prospective virtual screening.
Pérez-Nueno VI; Pettersson S; Ritchie DW; Borrell JI; Teixidó J
J Chem Inf Model; 2009 Apr; 49(4):810-23. PubMed ID: 19358515
[TBL] [Abstract][Full Text] [Related]
30. Pharmacophore modeling and virtual screening for the discovery of new transforming growth factor-beta type I receptor (ALK5) inhibitors.
Ren JX; Li LL; Zou J; Yang L; Yang JL; Yang SY
Eur J Med Chem; 2009 Nov; 44(11):4259-65. PubMed ID: 19640613
[TBL] [Abstract][Full Text] [Related]
31. Strategies for generating less toxic P-selectin inhibitors: pharmacophore modeling, virtual screening and counter pharmacophore screening to remove toxic hits.
Ananthula RS; Ravikumar M; Pramod AB; Madala KK; Mahmood SK
J Mol Graph Model; 2008 Nov; 27(4):546-57. PubMed ID: 18993099
[TBL] [Abstract][Full Text] [Related]
32. Energy-Based Pharmacophore and Three-Dimensional Quantitative Structure--Activity Relationship (3D-QSAR) Modeling Combined with Virtual Screening To Identify Novel Small-Molecule Inhibitors of Silent Mating-Type Information Regulation 2 Homologue 1 (SIRT1).
Pulla VK; Sriram DS; Viswanadha S; Sriram D; Yogeeswari P
J Chem Inf Model; 2016 Jan; 56(1):173-87. PubMed ID: 26636371
[TBL] [Abstract][Full Text] [Related]
33. 3D-QSAR studies of HDACs inhibitors using pharmacophore-based alignment.
Chen Y; Li H; Tang W; Zhu C; Jiang Y; Zou J; Yu Q; You Q
Eur J Med Chem; 2009 Jul; 44(7):2868-76. PubMed ID: 19136179
[TBL] [Abstract][Full Text] [Related]
34. Combined pharmacophore and structure-guided studies to identify diverse HSP90 inhibitors.
Sanam R; Tajne S; Gundla R; Vadivelan S; Machiraju PK; Dayam R; Narasu L; Jagarlapudi S; Neamati N
J Mol Graph Model; 2010 Feb; 28(6):472-7. PubMed ID: 20005756
[TBL] [Abstract][Full Text] [Related]
35. Fuzzy pharmacophore models from molecular alignments for correlation-vector-based virtual screening.
Renner S; Schneider G
J Med Chem; 2004 Sep; 47(19):4653-64. PubMed ID: 15341481
[TBL] [Abstract][Full Text] [Related]
36. Non-peptide angiotensin II receptor antagonists: chemical feature based pharmacophore identification.
Krovat EM; Langer T
J Med Chem; 2003 Feb; 46(5):716-26. PubMed ID: 12593652
[TBL] [Abstract][Full Text] [Related]
37. Novel chemical scaffolds of the tumor marker AKR1B10 inhibitors discovered by 3D QSAR pharmacophore modeling.
Kumar R; Son M; Bavi R; Lee Y; Park C; Arulalapperumal V; Cao GP; Kim HH; Suh JK; Kim YS; Kwon YJ; Lee KW
Acta Pharmacol Sin; 2015 Aug; 36(8):998-1012. PubMed ID: 26051108
[TBL] [Abstract][Full Text] [Related]
38. A three-dimensional pharmacophore modelling of ITK inhibitors and virtual screening for novel inhibitors.
Bagga V; Silakari O; Ghorela VS; Bahia MS; Rambabu G; Sarma J
SAR QSAR Environ Res; 2011 Mar; 22(1-2):171-90. PubMed ID: 21391146
[TBL] [Abstract][Full Text] [Related]
39. Discovery of new MurF inhibitors via pharmacophore modeling and QSAR analysis followed by in-silico screening.
Taha MO; Atallah N; Al-Bakri AG; Paradis-Bleau C; Zalloum H; Younis KS; Levesque RC
Bioorg Med Chem; 2008 Feb; 16(3):1218-35. PubMed ID: 17988876
[TBL] [Abstract][Full Text] [Related]
40. Multiple pharmacophore models combined with molecular docking: a reliable way for efficiently identifying novel PDE4 inhibitors with high structural diversity.
Chen Z; Tian G; Wang Z; Jiang H; Shen J; Zhu W
J Chem Inf Model; 2010 Apr; 50(4):615-25. PubMed ID: 20353193
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]